376 related articles for article (PubMed ID: 26307625)
61. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
McDermott DF; Cheng SC; Signoretti S; Margolin KA; Clark JI; Sosman JA; Dutcher JP; Logan TF; Curti BD; Ernstoff MS; Appleman L; Wong MK; Khushalani NI; Oleksowicz L; Vaishampayan UN; Mier JW; Panka DJ; Bhatt RS; Bailey AS; Leibovich BC; Kwon ED; Kabbinavar FF; Belldegrun AS; Figlin RA; Pantuck AJ; Regan MM; Atkins MB
Clin Cancer Res; 2015 Feb; 21(3):561-8. PubMed ID: 25424850
[TBL] [Abstract][Full Text] [Related]
62. PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma.
Carlsson J; Sundqvist P; Kosuta V; Fält A; Giunchi F; Fiorentino M; Davidsson S
Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):213-220. PubMed ID: 31058656
[TBL] [Abstract][Full Text] [Related]
63. Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?
Pichler R; Compérat E; Klatte T; Pichler M; Loidl W; Lusuardi L; Schmidinger M
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30934624
[TBL] [Abstract][Full Text] [Related]
64. Correlation of T Cell Immunoglobulin and ITIM Domain (TIGIT) and Programmed Death 1 (PD-1) with Clinicopathological Characteristics of Renal Cell Carcinoma May Indicate Potential Targets for Treatment.
Hong X; Wang X; Wang T; Zhang X
Med Sci Monit; 2018 Sep; 24():6861-6872. PubMed ID: 30262800
[TBL] [Abstract][Full Text] [Related]
65. Coexpression of lymphocyte-activation gene 3 and programmed death ligand-1 in tumor infiltrating immune cells predicts worse outcome in renal cell carcinoma.
Lee CH; Jung SJ; Seo WI; Chung JI; Lee DS; Jeong DH; Jeon Y; Choi I
Int J Immunopathol Pharmacol; 2022; 36():3946320221125588. PubMed ID: 36083857
[TBL] [Abstract][Full Text] [Related]
66. Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Krajewski KM; Albiges L; Awad MM; Bellmunt J; Hodi FS; Choueiri TK
Cancer Immunol Res; 2016 Jan; 4(1):12-7. PubMed ID: 26589768
[TBL] [Abstract][Full Text] [Related]
67. Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated protein 4 expressions together with clinicopathological findings in clear cell, papillary, and chromophobe types of renal cell carcinoma.
Inceman M; Toyran T; Bayazit Y; Izol V; Erdogan S
Pol J Pathol; 2022; 73(3):181-190. PubMed ID: 36734432
[TBL] [Abstract][Full Text] [Related]
68. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
Hara T; Miyake H; Hinata N; Fujisawa M
Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
[TBL] [Abstract][Full Text] [Related]
69. Impact of PD-L1 Protein Expression on Renal Cell Carcinoma Histo-differentiation.
Tziakou P; Theodoropoulos G; Tsiambas E; Zizi-Sermpetzoglou A; Peschos D; Mastronikoli S; Thomopoulou G; Thymara E; Kavantzas N; Lazaris AC
Anticancer Res; 2021 Aug; 41(8):3809-3813. PubMed ID: 34281840
[TBL] [Abstract][Full Text] [Related]
70. Sarcomatoid differentiation of renal cell carcinoma: a clinical case with literature review.
Kountourakis P; Kandylis K; Daskalopoulou D; Rigatos G
J BUON; 2008; 13(2):281-3. PubMed ID: 18555479
[TBL] [Abstract][Full Text] [Related]
71. Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models.
Cui S
Med Sci Monit; 2017 Jul; 23():3360-3366. PubMed ID: 28697172
[TBL] [Abstract][Full Text] [Related]
72. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
73. Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.
Xu W; Anwaier A; Liu W; Wei G; Su J; Tian X; Xia J; Qu Y; Zhao J; Zhang H; Ye D
Front Immunol; 2022; 13():953721. PubMed ID: 35979371
[TBL] [Abstract][Full Text] [Related]
74. [PD-L1 expression: An emerging biomarker in non-small cell lung cancer].
Adam J; Planchard D; Marabelle A; Soria JC; Scoazec JY; Lantuéjoul S
Ann Pathol; 2016 Jan; 36(1):94-102. PubMed ID: 26778219
[TBL] [Abstract][Full Text] [Related]
75. PD-L1 expression in papillary renal cell carcinoma.
Motoshima T; Komohara Y; Ma C; Dewi AK; Noguchi H; Yamada S; Nakayama T; Kitada S; Kawano Y; Takahashi W; Sugimoto M; Takeya M; Fujimoto N; Oda Y; Eto M
BMC Urol; 2017 Jan; 17(1):8. PubMed ID: 28086852
[TBL] [Abstract][Full Text] [Related]
76. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
[TBL] [Abstract][Full Text] [Related]
77. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
78. PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.
Abdel-Rahman O
Immunotherapy; 2016 Sep; 8(9):1081-9. PubMed ID: 27485080
[TBL] [Abstract][Full Text] [Related]
79. Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib.
Kunene V; Miscoria M; Pirrie S; Islam MR; Afshar M; Porfiri E
Clin Genitourin Cancer; 2014 Aug; 12(4):251-5. PubMed ID: 24560086
[TBL] [Abstract][Full Text] [Related]
80. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
